AKESO INC. O.N.
Research AKESO INC. O.N. (4RY) on Bullrun: market cap EUR 8.73B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4RY
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 8.73B
- Financial periodFY2025
- RevenueEUR 3.06B
- Revenue growth43.9%
- Net income-EUR 1.11B
- Free cash flow-EUR 1.73B
- Gross margin78.7%
Valuation Snapshot
latest market cap is EUR 8.73B.
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer.
Frequently asked questions
What is AKESO INC. O.N.'s market cap?
AKESO INC. O.N.'s market capitalization is EUR 8.73B.
What does AKESO INC. O.N. do?
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer;